疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2014年
11期
1140-1142
,共3页
朱琳燕%汪玉芳%陈世明%柯金勇
硃琳燕%汪玉芳%陳世明%柯金勇
주림연%왕옥방%진세명%가금용
氨磷汀%红细胞生成素%骨髓增生异常综合征%不良反应
氨燐汀%紅細胞生成素%骨髓增生異常綜閤徵%不良反應
안린정%홍세포생성소%골수증생이상종합정%불량반응
Amifostine%Erythropoietin%Myelodysplastic syndrome%Adverse reaction
目的：探讨氨磷汀联合红细胞生成素治疗骨髓增生异常综合征（ MDS）的临床疗效。方法对血液内科收治的MDS患者28例采用随机数字表法分为联合组和对照组各14例，对照组采用氨磷汀0ú．5 g静脉滴注，联合组在对照组基础上加用红细胞生成素6000 U皮下注射，3次／周，疗程3个月，比较2组患者的临床疗效。结果治疗前2组的白细胞、血小板、血红蛋白比较差异不显著（ P ＞0．05），治疗后2组均升高，但差异亦无统计学意义（ P ＞0．05），治疗3个月后，脱离输血＋输血量减少50％以上的患者比例联合组为78．57％，高于对照组的35．72％，差异有统计学意义（χ2＝5．250， P ＝0．022）。联合组近期总有效率为78．57％，高于对照组的64．29％，但差异无统计学意义（χ2＝0．700， P ＝0．403）。2组患者的1年生存率均为100％，2年生存率与3年生存率比较，联合组均高于对照组（78．57％vs 57．14％，57．14％vs．35．71％），但差异无统计学意义（ P ＞0．05）。联合组中位生存时间为32个月，显著长于对照组的25个月（χ2＝3．532， P ＝0．038）。结论氨磷汀联合红细胞生成素治疗MDS对改善患者的血象及生存时间有一定作用。
目的：探討氨燐汀聯閤紅細胞生成素治療骨髓增生異常綜閤徵（ MDS）的臨床療效。方法對血液內科收治的MDS患者28例採用隨機數字錶法分為聯閤組和對照組各14例，對照組採用氨燐汀0ú．5 g靜脈滴註，聯閤組在對照組基礎上加用紅細胞生成素6000 U皮下註射，3次／週，療程3箇月，比較2組患者的臨床療效。結果治療前2組的白細胞、血小闆、血紅蛋白比較差異不顯著（ P ＞0．05），治療後2組均升高，但差異亦無統計學意義（ P ＞0．05），治療3箇月後，脫離輸血＋輸血量減少50％以上的患者比例聯閤組為78．57％，高于對照組的35．72％，差異有統計學意義（χ2＝5．250， P ＝0．022）。聯閤組近期總有效率為78．57％，高于對照組的64．29％，但差異無統計學意義（χ2＝0．700， P ＝0．403）。2組患者的1年生存率均為100％，2年生存率與3年生存率比較，聯閤組均高于對照組（78．57％vs 57．14％，57．14％vs．35．71％），但差異無統計學意義（ P ＞0．05）。聯閤組中位生存時間為32箇月，顯著長于對照組的25箇月（χ2＝3．532， P ＝0．038）。結論氨燐汀聯閤紅細胞生成素治療MDS對改善患者的血象及生存時間有一定作用。
목적：탐토안린정연합홍세포생성소치료골수증생이상종합정（ MDS）적림상료효。방법대혈액내과수치적MDS환자28례채용수궤수자표법분위연합조화대조조각14례，대조조채용안린정0ú．5 g정맥적주，연합조재대조조기출상가용홍세포생성소6000 U피하주사，3차／주，료정3개월，비교2조환자적림상료효。결과치료전2조적백세포、혈소판、혈홍단백비교차이불현저（ P ＞0．05），치료후2조균승고，단차이역무통계학의의（ P ＞0．05），치료3개월후，탈리수혈＋수혈량감소50％이상적환자비례연합조위78．57％，고우대조조적35．72％，차이유통계학의의（χ2＝5．250， P ＝0．022）。연합조근기총유효솔위78．57％，고우대조조적64．29％，단차이무통계학의의（χ2＝0．700， P ＝0．403）。2조환자적1년생존솔균위100％，2년생존솔여3년생존솔비교，연합조균고우대조조（78．57％vs 57．14％，57．14％vs．35．71％），단차이무통계학의의（ P ＞0．05）。연합조중위생존시간위32개월，현저장우대조조적25개월（χ2＝3．532， P ＝0．038）。결론안린정연합홍세포생성소치료MDS대개선환자적혈상급생존시간유일정작용。
Objective To investigate the effect of amifostine combined with erythropoietin in the treatment of myelo -dysplastic syndrome ( MDS) .Methods Twenty-eight MDS patients from the Department of internal medicine were randomly divided into combined group and control group with 14 cases in each group , the control group used amifostine intravenous infu-sion of 0.5 g, the combined group besides the treatment as the control group , also use of erythropoietin 6 000 U subcutaneous injections, 3 times/week, the course of treatment was 3 months, the clinical curative effect of 2 groups were compared .Re-sults Before treatment, white blood cells, platelets, hemoglobin did not show significant difference between the 2 groups (P >0.05), after treatment, these indices in the 2 groups were increased but the difference was not statistically significant (P >0.05), after 3 months of treatment, blood transfusion and transfusion volume reduced more than 50%’s proportion in the combined group was 78.57%, higher than 35.72%in the control group, the difference was statistically significant (χ2 =5.250, P =0.022).The combined group’s total effective rate was 78.57%, higher than 64.29%in the control group, but the difference was not statistically significant (χ2 =0.700, P =0.403).The 1 year survival rate of 2 groups of patients were 100%, 2 year survival rate , compared with the 3 year survival rate , the combined group were higher than that of control group (78.57%vs.57.14%, 57.14%vs.35.71%), but the difference was not statistically significant ( P >0.05).Combined group’s median survival time was 32 months, significantly longer than the 25 months in the control group (χ2 =3.532, P =0.038).Conclusion Amifostine combined with erythropoietin in the treatment of MDS have certain effect to improve the blood and the survival time of the patients .
